Clearside Biomedical, Inc.
CLSD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.07 | -0.15 | 0.67 |
| FCF Yield | -26.37% | -7.59% | -8.26% | -7.91% |
| EV / EBITDA | -4.35 | -32.40 | -23.38 | -22.48 |
| Quality | ||||
| ROIC | -76.07% | -28.17% | -34.62% | -34.52% |
| Gross Margin | 100.00% | 82.93% | 89.36% | 51.31% |
| Cash Conversion Ratio | 0.92 | 1.05 | 0.71 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.62% | 37.06% | 56.39% | 7.84% |
| Free Cash Flow Growth | -15.88% | 18.89% | -2.32% | 4.49% |
| Safety | ||||
| Net Debt / EBITDA | 1.92 | 5.36 | -8.51 | -6.98 |
| Interest Coverage | -2.74 | -1.29 | -1.95 | -2.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 119.10 | -1,060.37 | -635.19 | -727.93 |